retatrutide phase 2 results 2024 2025 Eli Lilly just announced striking 3 for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% The Effect of Retatrutide on

This latest study adds to a growing body of data on the positive cardiovascular effects of GLP-1-RAs beyond their initial indications for diabetes and weight management

Varicocele vein ligation in 565 patients under local anesthesia: a long-term review of technique, results and complications in light of proposed management by laparoscopy

Practical strategies can significantly reduce nausea associated with GLP-1 receptor agonist therapy, improving treatment adherence and patient outcomes

presents the progress of a screening platform focused on the discovery of small-molecule compounds that can enhance the replication of beta cells